Agomelatine might be more appropriate for elderly, depressed, type 2 diabetes mellitus patients than paroxetine/fluoxetine.
Zihong Liang, Yanbo Jia, Lizhen Zhao, Runxiu Zhu, Xuemei He, Bagen Tong, Fan Yang, Lixia Hao, Pengfei Cui, Jun Yuan
Author Information
Zihong Liang: Department of Psychiatry, Inner Mongolia Autonomous Region People's Hospital, Huhhot, Inner Mongolia 010017, People's Republic of China.
Yanbo Jia: Department of Orthopaedics, The Second Affiliated Hospital of Inner Mongolia Medical University, Huhhot, Inner Mongolia 010030, People's Republic of China.
Lizhen Zhao: Department of Psychiatry, Inner Mongolia Autonomous Region People's Hospital, Huhhot, Inner Mongolia 010017, People's Republic of China.
Runxiu Zhu: Department of Neurology, Inner Mongolia Autonomous Region People's Hospital, Huhhot, Inner Mongolia 010017, People's Republic of China.
Xuemei He: Department of Psychiatry, Inner Mongolia Autonomous Region People's Hospital, Huhhot, Inner Mongolia 010017, People's Republic of China.
Bagen Tong: Department of Psychiatry, Inner Mongolia Autonomous Region People's Hospital, Huhhot, Inner Mongolia 010017, People's Republic of China.
Fan Yang: Department of Psychiatry, Inner Mongolia Autonomous Region People's Hospital, Huhhot, Inner Mongolia 010017, People's Republic of China.
Lixia Hao: Department of Psychiatry, Inner Mongolia Autonomous Region People's Hospital, Huhhot, Inner Mongolia 010017, People's Republic of China.
Pengfei Cui: Department of Psychiatry, Inner Mongolia Autonomous Region Third Hospital, Huhhot, Inner Mongolia 010050, People's Republic of China.
Jun Yuan: Department of Neurology, Inner Mongolia Autonomous Region People's Hospital, Huhhot, Inner Mongolia 010017, People's Republic of China.
Agomelatine was a novel and melatonergic antidepressant. The present study was conducted to find out whether age was an important factor for agomelatine in treating depressed type 2 diabetes mellitus (T2DM) patients. In total, 193 depressed T2DM patients were included. There were 84 patients ranged from 27 years old to 49 years old (age phase I) ( = 44 receiving agomelatine, = 40 receiving paroxetine or fluoxetine), and 109 patients ranged from 50 years old to 70 years old (age phase II) ( = 56 receiving agomelatine, = 53 receiving paroxetine or fluoxetine). The Hamilton Depression Rating Scale (HDRS) score, Hamilton Anxiety Rating Scale (HARS) score, fasting plasma glucose (FPG), hemoglobin A1c (HbA1c) level and body mass index (BMI) were assessed after 12 weeks treatment. After treatment, we found that among patients in age phase I, there were no significant differences in final average HDRS score, HARS score, FPG, HbA1c level, BMI, response rate and remission rate between the two groups. However, among patients in age phase II, compared to patients receiving paroxetine or fluoxetine, patients receiving agomelatine had the significantly lower average HDRS score, HARS score, HbA1c level and BMI, and significantly higher response rate and remission rate. The incidence of treatment-related adverse events was similar between the two groups in both age phases. These results suggested that age was an important factor for agomelatine in treating depressed T2DM patients. Compared to paroxetine/fluoxetine, agomelatine might be more appropriate for elderly depressed T2DM patients.
